|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global Cancer Statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maomao C, He L, Dianqin S, Siyi H, Xinxin
Y, Fan Y, Shaoli Z, Changfa X, Lin L, Ji P and Wanqing C: Current
cancer burden in China: Epidemiology, etiology, and prevention.
Cancer Biol Med. 19:1121–1138. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Njei B, McCarty TR and Birk JW: Trends in
esophageal cancer survival in United States adults from 1973 to
2009: A SEER database analysis. J Gastroenterol Hepatol.
31:1141–1146. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sasaki Y and Kato K: Chemoradiotherapy for
esophageal squamous cell cancer. Jpn J Clin Oncol. 46:805–810.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang FL and Yu SJ: Esophageal cancer:
Risk factors, genetic association, and treatment. Asian J Surg.
41:210–215. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van Hagen P, Hulshof MC, van Lanschot JJ,
Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ,
Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J
Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Teoh AY, Chiu PW, Yeung WK, Liu SY, Wong
SK and Ng EK: Long-term survival outcomes after definitive
chemoradiation versus surgery in patients with resectable squamous
carcinoma of the esophagus: Results from a randomized controlled
trial. Ann Oncol. 24:165–171. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen P, Zhao X, Zhou F, Song X, Hu S, Jin
Y, Wang X, Han X, Fan Z, Wang R, et al: Characterization of 500
Chinese patients with cervical esophageal cancer by
clinicopathological and treatment outcomes. Cancer Biol Med.
17:219–226. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cooper JS, Guo MD, Herskovic A, Macdonald
JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler
JJ, Spencer S, et al: Chemoradiotherapy of locally advanced
esophageal cancer: Long-term follow-up of a prospective randomized
trial (RTOG 85-01). Radiation therapy oncology group. JAMA.
281:1623–1627. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zeng H, Zhang F, Sun Y, Li S and Zhang W:
Treatment options for neoadjuvant strategies of esophageal squamous
cell carcinoma (review). Mol Clin Oncol. 20:42023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ferri L: Clinical T4b esophageal cancer:
Can we make an ‘unresectable’ tumour resectable? Ann Surg Oncol.
27:329–330. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamaguchi S, Morita M, Yamamoto M,
Egashira A, Kawano H, Kinjo N, Tsujita E, Minami K, Ikebe M, Ikeda
Y, et al: Long-term outcome of definitive chemoradiotherapy and
induction chemoradiotherapy followed by surgery for T4 esophageal
cancer with tracheobronchial invasion. Ann Surg Oncol.
25:3280–3287. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yokota T, Kato K, Hamamoto Y, Tsubosa Y,
Ogawa H, Ito Y, Hara H, Ura T, Kojima T, Chin K, et al: A 3-year
overall survival update from a phase 2 study of chemoselection with
DCF and subsequent conversion surgery for locally advanced
unresectable esophageal cancer. Ann Surg Oncol. 27:460–467. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mitchell KG, Nelson DB, Corsini EM,
Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B,
Walsh GL, et al: Morbidity following salvage esophagectomy for
squamous cell carcinoma: The MD Anderson experience. Dis Esophagus.
33:doz0672020.PubMed/NCBI
|
|
15
|
Miyata H, Sugimura K, Kanemura T, Takeoka
T, Sugase T, Tanaka K, Makino T, Yamashita K, Yamasaki M, Motoori
M, et al: Salvage surgery for recurrent disease after definitive
chemoradiotherapy for esophageal squamous cell carcinoma. Ann Surg
Oncol. 29:5657–5665. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky
TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP:
INT 0123 (radiation therapy oncology group 94-05) phase III trial
of combined-modality therapy for esophageal cancer: High-dose
versus standard-dose versus standard-dose radiation therapy. J Clin
Oncol. 20:1167–1174. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ji Y, Du X, Zhu W, Yang Y, Ma J, Zhang L,
Li J, Tao H, Xia J, Yang H, et al: Efficacy of concurrent
chemoradiotherapy with S-1 vs radiotherapy alone for older patients
with esophageal cancer: A multicenter randomized phase 3 clinical
trial. JAMA Oncol. 7:1459–1466. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Conroy T, Galais MP, Raoul JL, Bouché O,
Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay
I, Michel P, et al: Definitive chemoradiotherapy with FOLFOX versus
fluorouracil and cisplatin in patients with oesophageal cancer
(PRODIGE5/ACCORD17): Final results of a randomised, phase 2/3
trial. Lancet Oncol. 15:305–314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Greene FL, Page DL, Fleming ID, Fritz AG,
Balch CM, Haller DG and Morrow M: Esophagus. American Joint
Committee on Cancer (AJCC) cancer staging manual. 6th edition. New
York, NY: Springer; pp. 167–178. 2002
|
|
20
|
Rades D, Zwaan I, Soror T, Idel C, Pries
R, Bruchhage KL, Hakim SG and Yu NY: Chemoradiation with cisplatin
vs carboplatin for squamous cell carcinoma of the head and neck
(SCCHN). Cancers (Basel). 15:32782023. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ai D, Ye J, Wei S, Li Y, Luo H, Cao J, Zhu
Z, Zhao W, Lin Q, Yang H, et al: Comparison of 3 paclitaxel-based
chemoradiotherapy regimens for patients with locally advanced
esophageal squamous cell cancer: A randomized clinical trial. JAMA
Netw Open. 5:e2201202022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Higuchi K, Komori S, Tanabe S, Katada C,
Azuma M, Ishiyama H, Sasaki T, Ishido K, Katada N, Hayakawa K, et
al: Definitive chemoradiation therapy with docetaxel, cisplatin,
and 5-fluorouracil (DCF-R) in advanced esophageal cancer: A phase 2
trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys. 89:872–879.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou XL, Yu CH, Wang WW, Ji FZ, Xiong YZ,
Zhu WG and Tong YS: Concurrent chemoradiotherapy with S-1 compared
with concurrent chemoradiotherapy with docetaxel and cisplatin for
locally advanced esophageal squamous cell carcinoma. Radiat Oncol.
16:942021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang X, Han W, Zhang W, Wang X, Ge X, Lin
Y, Zhou H, Hu M, Wang W, Liu K, et al: Effectiveness of S-1-based
chemoradiotherapy in patients 70 years and older with esophageal
squamous cell carcinoma: A randomized clinical trial. JAMA Netw
Open. 6:e23126252023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Gong Y, Diao P, Huang Q, Wen Y, Lin
B, Cai H, Tian H, He B, Ji L, et al: Comparison of the clinical
efficacy between single-agent and dual-agent concurrent
chemoradiotherapy in the treatment of unresectable esophageal
squamous cell carcinoma: A multicenter retrospective analysis.
Radiat Oncol. 13:122018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Herskovic A, Martz K, al-Sarraf M,
Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L
and Emami B: Combined chemotherapy and radiotherapy compared with
radiotherapy alone in patients with cancer of the esophagus. N Engl
J Med. 326:1593–1598. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Itami J, Murakami N, Watanabe M, Sekii S,
Kasamatsu T, Kato S, Hirowatari H, Ikushima H, Ando K, Ohno T, et
al: Combined interstitial and intracavitary high-dose rate
brachytherapy of cervical cancer. Front Oncol. 11:8098252022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lan W, Lihong L, Chun H, Shutang L, Qi W,
Liang X, Xiaoning L and Likun L: Comparison of efficacy and safety
between simultaneous integrated boost intensity-modulated
radiotherapy and standard-dose intensity-modulated radiotherapy in
locally advanced esophageal squamous cell carcinoma: A
retrospective study. Strahlenther Onkol. 198:802–811. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen Y, Zhu HP, Wang T, Sun CJ, Ge XL, Min
LF, Zhang XW, Jia QQ, Yu J, Yang JQ, et al: What is the optimal
radiation dose for non-operable esophageal cancer? Dissecting the
evidence in a meta-analysis. Oncotarget. 8:89095–89107. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu Y, Dong B, Zhu W, Li J, Huang R, Sun Z,
Yang X, Liu L, He H, Liao Z, et al: A phase III multicenter
randomized clinical trial of 60 Gy versus 50 Gy radiation dose in
concurrent chemoradiotherapy for inoperable esophageal squamous
cell carcinoma. Clin Cancer Res. 28:1792–1799. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hulshof MCCM, Geijsen ED, Rozema T,
Oppedijk V, Buijsen J, Neelis KJ, Nuyttens JJME, van der Sangen
MJC, Jeene PM, Reinders JG, et al: Randomized study on dose
escalation in definitive chemoradiation for patients with locally
advanced esophageal cancer (ARTDECO study). J Clin Oncol.
39:2816–2824. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Crehange G, M'vondo C, Bertaut A, Pereira
R, Rio E, Peiffert D, Gnep K, Benezery K, Ronchin P, Noel G, et al:
Exclusive chemoradiotherapy with or without radiation dose
escalation in esophageal cancer: Multicenter phase 2/3 randomized
trial CONCORDE (PRODIGE-26). Int J Radiat Oncol Biol Phys. 111
(Suppl):S52021. View Article : Google Scholar
|
|
33
|
Chandra A, Guerrero TM, Liu HH, Tucker SL,
Liao Z, Wang X, Murshed H, Bonnen MD, Garg AK, Stevens CW, et al:
Feasibility of using intensity-modulated radiotherapy to improve
lung sparing in treatment planning for distal esophageal cancer.
Radiother Oncol. 77:247–253. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nicolini G, Ghosh-Laskar S, Shrivastava
SK, Banerjee S, Chaudhary S, Agarwal JP, Munshi A, Clivio A,
Fogliata A, Mancosu P, et al: Volumetric modulation arc
radiotherapy with flattening filter-free beams compared with static
gantry IMRT and 3D conformal radiotherapy for advanced esophageal
cancer: A feasibility study. Int J Radiation Oncol Biol Phys.
84:553–560. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang X, Bai H, Li R, Wang L, Zhang W,
Liang J and Yuan Z: High versus standard radiation dose of
definitive concurrent chemoradiotherapy for esophageal cancer: A
systematic review and meta-analysis of randomized clinical trials.
Radiother Oncol. 180:1094632023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Welsh J, Palmer MB, Ajani JA, Liao Z,
Swisher SG, Hofstetter WL, Allen PK, Settle SH, Gomez D, Likhacheva
A, et al: Esophageal cancer dose escalation using a simultaneous
integrated boost technique. Int J Radiat Oncol Biol Phys.
82:468–474. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang R, Liu S, Chen B and Xi M: Recent
advances in combination of immunotherapy and chemoradiotherapy for
locally advanced esophageal squamous cell carcinoma. Cancers
(Basel). 14:51682022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gao XS, Qiao X, Wu F, Cao L, Meng X, Dong
Z, Wang X, Gao G, Wu TT, Komaki R and Chang JY: Pathological
analysis of clinical target volume margin for radiotherapy in
patients with esophageal and gastroesophageal junction carcinoma.
Int J Radiat Oncol Biol Phys. 67:389–396. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang H and Hu B: Recent advances in early
esophageal cancer: Diagnosis and treatment based on endoscopy.
Postgrad Med. 133:665–673. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Vesprini D, Ung Y, Dinniwell R, Breen S,
Cheung F, Grabarz D, Kamra J, Mah K, Mansouri A, Pond G, et al:
Improving observer variability in target delineation for
gastro-oesophageal cancer-the role of (18F)fluoro-2-deoxy-D-glucose
positron emission tomography/computed tomography. Clin Oncol (R
Coll Radiol). 20:631–638. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pijl JP, Nienhuis PH, Kwee TC, Glaudemans
AWJM, Slart RHJA and Gormsen LC: Limitations and pitfalls of
FDG-PET/CT in infection and inflammation. Semin Nucl Med.
51:633–645. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fernandez P, Zanotti-Fregonara P, Eimer S,
Gimbert E, Monteil P, Penchet G, Lamare F, Perez P, Vimont D,
Ledure S, et al: Combining 3′-Deoxy-3′-[18F] fluorothymidine and
MRI increases the sensitivity of glioma volume detection. Nucl Med
Commun. 40:1066–1071. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Han D, Yu J, Yu Y, Zhang G, Zhong X, Lu J,
Yin Y, Fu Z, Mu D, Zhang B, et al: Comparison of
(18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in
delineating gross tumor volume by optimal threshold in patients
with squamous cell carcinoma of thoracic esophagus. Int J Radiat
Oncol Biol Phys. 76:1235–1241. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Guo Y, Li J, Zhang P and Zhang Y: A
comparative study of target volumes based on 18F-FDG
PET-CT and ten phases of 4DCT for primary thoracic squamous
esophageal cancer. Onco Targets Ther. 10:177–184. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vollenbrock SE, Voncken FEM, van Dieren
JM, Lambregts DMJ, Maas M, Meijer GJ, Goense L, Mook S, Hartemink
KJ, Snaebjornsson P, et al: Diagnostic performance of MRI for
assessment of response to neoadjuvant chemoradiotherapy in
oesophageal cancer. Br J Surg. 106:596–605. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li H, Li F, Li J, Zhu Y, Zhang Y, Guo Y,
Xu M, Shao Q and Liu X: Comparison of gross target volumes based on
four-dimensional CT, positron emission tomography-computed
tomography, and magnetic resonance imaging in thoracic esophageal
cancer. Cancer Med. 9:5353–5361. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Van De Voorde L, Larue RT, Pijls M,
Buijsen J, Troost EG, Berbée M, Sosef M, van Elmpt W, Schraepen MC,
Vanneste B, et al: A qualitative synthesis of the evidence behind
elective lymph node irradiation in oesophageal cancer. Radiother
Oncol. 113:166–174. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tamamura H, Hasatani K, Matsumoto S, Asahi
S, Tatebe H, Sato Y, Matsusita K, Tameshige Y, Maeda Y, Sasaki M,
et al: Evaluation of exposure doses of elective nodal irradiation
in chemoradiotherapy for advanced esophageal cancer. Cancers
(Basel). 15:8602023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhao KL, Ma JB, Liu G, Wu KL, Shi XH and
Jiang GL: Three-dimensional conformal radiation therapy for
esophageal squamous cell carcinoma: Is elective nodal irradiation
necessary? Int J Radiat Oncol Biol Phys. 76:446–451. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang J, Wu Y, Zhang W, Chen Y, Liu Q, Jing
S, Zhang J, Wu F, Wang J and Qiao X: Elective nodal irradiation
versus involved-field irradiation for stage II–IV cervical
esophageal squamous cell carcinoma patients undergoing definitive
concurrent chemoradiotherapy: a retrospective propensity study with
8-year survival outcomes. Radiat Oncol. 18:1422023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chen X, Zhang Y, Zhou X, Wang M, Na F,
Zhou L, Xu Y, Zou B, Xue J, Liu Y and Gong Y: Involved-field
irradiation or elective-nodal irradiation in neoadjuvant
chemo-radiotherapy for locally-advanced esophageal cancer:
Comprehensive analysis for dosimetry, treatment-related
complications, impact on lymphocyte, patterns of failure and
survival. Front Oncol. 13:12749242023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lyu J, LI T, Zhang X, Tian Z, Wang X, Chen
L, LU B, Chen H, Yang J, Wang Q, et al: Involved field irradiation
(IFI) versus elective nodal irradiation (ENI) in combination with
concurrent chemotherapy for esophageal thoracic squamous cell
cancer: A prospective, randomized, multicenter, controlled study.
Chin J Radiat Oncol. 7:245–249. 2018.
|
|
53
|
Rahim MK, Okholm TLH, Jones KB, McCarthy
EE, Liu CC, Yee JL, Tamaki SJ, Marquez DM, Tenvooren I, Wai K, et
al: Dynamic CD8+ T cell responses to cancer immunotherapy in human
regional lymph nodes are disrupted in metastatic lymph nodes. Cell.
186:1127–1143. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang X, Bai H, Gao M, Guan Y, Yu L, Li J,
Dong Y, Song Y, Tao Z, Meng M, et al: Impact of radiation dose to
the immune system on disease progression and survival for
early-stage non-small cell lung cancer treated with stereotactic
body radiation therapy. Radiother Oncol. 186:1098042023. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Reid TD, Davies IL, Mason J, Roberts SA,
Crosby TD and Lewis WG: Stage for stage comparison of recurrence
patterns after definitive chemoradiotherapy or surgery for
oesophageal carcinoma. Clin Oncol (R Coll Radiol). 24:617–624.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wang Z, Guo J, Qin J, Zhang H, Zhao Y, Lu
Y, Yan X, Zhang F, Zhang Z, Zhang T, et al: Accuracy of 3-T MRI for
preoperative T staging of esophageal cancer after neoadjuvant
chemotherapy, with histopathologic correlation. Am J Roentgenol.
212:788–795. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kim SW, Kim IK and Lee SH: Role of
hyperoxic treatment in cancer. Exp Biol Med (Maywood). 245:851–860.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cavalieri S and Licitra L: Induction
chemotherapy is the best timekeeper in nasopharyngeal carcinoma.
Cancer. 126:3624–3626. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Qiu J, Lin H, Yu Y, Ke D, Li H, Zheng H,
Zheng Q, Wang Z, Lin M, Yang J, et al: Clinical outcomes and
toxicities of locally advanced esophageal squamous cell carcinoma
patients treated with early thoracic radiation therapy after
induction chemotherapy. Int J Clin Oncol. 28:550–564. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang XS, Xi M, Bu SS, Xu G and Ge H:
Comparative analysis between induction chemotherapy combined with
concurrent chemoradiotherapy and chemoradiotherapy alone for
thoracic esophageal squamous cell carcinoma. Chin J Radiat Oncol.
28:90–95. 2019.
|
|
61
|
Minsky BD, Neuberg D, Kelsen DP, Pisansky
TM, Ginsberg R and Benson A III: Neoadjuvant chemotherapy plus
concurrent chemotherapy and high-dose radiation for squamous cell
carcinoma of the esophagus: A preliminary analysis of the phase II
intergroup trial 0122. J Clin Oncol. 14:149–155. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Liu S, Luo L, Zhao L, Zhu Y, Liu H, Li Q,
Cai L, Hu Y, Qiu B, Zhang L, et al: Induction chemotherapy followed
by definitive chemoradiotherapy versus chemoradiotherapy alone in
esophageal squamous cell carcinoma: A randomized phase II trial.
Nat Commun. 12:40142021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Chan WL, Choi CW, Wong IY, Tsang TH, Lam
AT, Tse RP, Chan KK, Wong C, Law BT, Cheung EE, et al: Docetaxel,
cisplatin, and 5-FU triplet therapy as conversion therapy for
locoregionally advanced unresectable esophageal squamous cell
carcinoma. Ann Surg Oncol. 30:861–870. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Xi M, Liao Z, Deng W, Komaki R, Ho L and
Lin SH: Recursive partitioning analysis identifies pretreatment
risk groups for the utility of induction chemotherapy before
definitive chemoradiation therapy in esophageal cancer. Int J
Radiat Oncol Biol Phys. 99:407–416. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wang J, Xiao L, Wang S, Pang Q and Wang J:
Addition of induction or consolidation chemotherapy in definitive
concurrent chemoradiotherapy versus concurrent chemoradiotherapy
alone for patients with unresectable esophageal cancer: A
systematic review and meta-analysis. Front Oncol. 11:6652312021.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Waters JK and Reznik SI: Update on
management of squamous cell esophageal cancer. Curr Oncol Rep.
24:375–385. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Xia X, Wu M, Gao Q, Sun X and Ge X:
Consolidation chemotherapy rather than induction chemotherapy can
prolong the survival rate of inoperable esophageal cancer patients
who received concurrent chemoradiotherapy. Curr Oncol.
29:6342–6349. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhang AD, Su XH, Shi GF, Han C, Wang L,
Liu H, Zhang J and Zhang RH: Survival comparision of
three-dimensional radiotherapy alone vs chemoradiotherapy for
esophageal squamous cell carcinoma. Arch Med Res. 51:419–428. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Xia X, Liu Z, Qin Q, Di X, Zhang Z, Sun X
and Ge X: Long-term survival in nonsurgical esophageal cancer
patients who received consolidation chemotherapy compared with
patients who received concurrent chemoradiotherapy alone: A
systematic review and meta-analysis. Front Oncol. 10:6046572021.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Chen Y, Guo L, Cheng X, Wang J, Zhang Y,
Wang Y, Ke S and Shi W: With or without consolidation chemotherapy
using cisplatin/5-FU after concurrent chemoradiotherapy in stage
II–III squamous cell carcinoma of the esophagus: A propensity
score-matched analysis. Radiother Oncol. 129:154–160. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Zhao Z, Zhang Y, Wang X, Geng X, Zhu L and
Li M: Clinical response to chemoradiotherapy in esophageal
carcinoma is associated with survival and benefit of consolidation
chemotherapy. Cancer Med. 9:5881–5888. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wu Z, Zheng Q, Chen H, Xiang J, Hu H, Li
H, Pan Y, Peng Y, Yao X, Liu P, et al: Efficacy and safety of
neoadjuvant chemotherapy and immunotherapy in locally resectable
advanced esophageal squamous cell carcinoma. J Thorac Dis.
13:3518–3528. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Sun JM, Shen L, Shah MA, Enzinger P,
Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, et al:
Pembrolizumab plus chemotherapy versus chemotherapy alone for
first-line treatment of advanced oesophageal cancer (KEYNOTE-590):
A randomised, placebo-controlled, phase 3 study. Lancet.
398:759–771. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Peng F, Bao Y, Cheng C, Niu S, Song W, Li
Y, Yu H, Xing X, Feng S, Wang X, et al: Induction chemotherapy plus
camrelizumab followed by concurrent chemoradiotherapy in patients
with unresectable locally advanced esophageal squamous cell
carcinoma (ImpactCRT): A single-arm, phase II trial. J Clin Oncol.
41 (Suppl 16):e160672023. View Article : Google Scholar
|
|
75
|
Jing Z, Du D, Zhang N, Dai H, Wang X, Hua
Y and Wu S: Combination of radiation therapy and anti-PD-1 antibody
SHR-1210 in treating patients with esophageal squamous cell cancer.
Int J Radiat Oncol Biol Phys. 102:E312018. View Article : Google Scholar
|
|
76
|
Zhang W, Yan C, Gao X, Li X, Cao F, Zhao
G, Zhao J, Er P, Zhang T, Chen X, et al: Safety and feasibility of
radiotherapy plus camrelizumab for locally advanced esophageal
squamous cell carcinoma. Oncologist. 26:e1110–e1124. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhang W, Yan C, Zhang T, Chen X, Dong J,
Zhao J, Han D, Wang J, Zhao G, Cao F, et al: Addition of
camrelizumab to docetaxel, cisplatin, and radiation therapy in
patients with locally advanced esophageal squamous cell carcinoma:
A phase 1b study. OncoImmunology. 10:19714182021. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zhu Y, Wen J, Li Q, Chen B, Zhao L, Liu S,
Yang Y, Wang S, Lv Y, Li J, et al: Toripalimab combined with
definitive chemoradiotherapy in locally advanced oesophageal
squamous cell carcinoma (EC-CRT-001): A single-arm, phase 2 trial.
Lancet Oncol. 24:371–382. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Calabrò L, Morra A, Giannarelli D, Amato
G, D'Incecco A, Covre A, Lewis A, Rebelatto MC, Danielli R,
Altomonte M, et al: Tremelimumab combined with durvalumab in
patients with mesothelioma (NIBIT-MESO-1): An open-label,
non-randomised, phase 2 study. Lancet Respir Med. 6:451–460. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Kelley RK, Sangro B, Harris W, Ikeda M,
Okusaka T, Kang YK, Qin S, Tai DWM, Lim HY, Yau T, et al: Safety,
efficacy, and pharmacodynamics of tremelimumab plus durvalumab for
patients with unresectable hepatocellular carcinoma: Randomized
expansion of a phase I/II study. J Clin Oncol. 39:2991–3001. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Park S, Oh D, Choi YL, Chi SA, Kim K, Ahn
MJ and Sun JM: Durvalumab and tremelimumab with definitive
chemoradiotherapy for locally advanced esophageal squamous cell
carcinoma. Cancer. 128:2148–2158. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC cancer staging manual. 7th edition.
New York, NY: Springer; 2010
|
|
83
|
Kelly RJ, Ajani JA, Kuzdzal J, Zander T,
Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre
A, et al: Adjuvant nivolumab in resected esophageal or
gastroesophageal junction cancer. N Engl J Med. 384:1191–1203.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Wang J, Cheng Y, Wu Y, Cao F, Liu Q and
Gao G: 978P A prospective study of camrelizumab monotherapy
following definitive concurrent chemoradiotherapy in patients with
unresectable locally advanced esophageal squamous cell cancer. Ann
Oncol. 32 (Suppl 5):S8382021. View Article : Google Scholar
|
|
85
|
Bando H, Kumagai S, Kotani D, Saori M,
Habu T, Tsushima T, Hara H, Kadowaki S, Kato K, Chin K, et al:
1211P A multicenter phase II study of atezolizumab monotherapy
following definitive chemoradiotherapy for unresectable locally
advanced esophageal squamous cell carcinoma (EPOC1802). Ann Oncol.
33 (Suppl 7):S1102–S1103. 2022. View Article : Google Scholar
|
|
86
|
Yang YM, Hong P, Xu WW, He QY and Li B:
Advances in targeted therapy for esophageal cancer. Signal
Transduct Target Ther. 5:2292020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhao G, Feng L, Ye T, Liu Y, Fan L, Ye C
and Chen J: Cetuximab enhances radiosensitivity of esophageal
squamous cell carcinoma cells by G2/M cycle arrest and DNA repair
delay through inhibiting p-EGFR and p-ERK. Thorac Cancer.
14:2127–2138. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Brenner B, Purim O, Gordon N, Goshen-Lago
T, Idelevich E, Kashtan H, Menasherov N, Fenig E, Sulkes A and
Kundel Y: The addition of cetuximab to preoperative
chemoradiotherapy for locally advanced esophageal squamous cell
carcinoma is associated with high rate of long term survival:
Mature results from a prospective phase Ib/II trial. Radiother
Oncol. 134:74–80. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Crosby T, Hurt CN, Falk S, Gollins S,
Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI,
et al: Chemoradiotherapy with or without cetuximab in patients with
oesophageal cancer (SCOPE1): A multicentre, phase 2/3 randomised
trial. Lancet Oncol. 14:627–637. 2013. View Article : Google Scholar : PubMed/NCBI
|
